FDA Grants Priority Review for Levo Therapeutics ’ New Drug Application for LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome

CHICAGO, IL, July 6, 2021 (Newswire.com) – Levo Therapeutics, Inc., a biotechnology company dedicated to using genetic insights to advance treatments for Prader-Willi syndrome (PWS) and related disorders, announced today that the U.S....
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news